Table 1.
Demographic and baseline characteristic data for endometrial cancer cases and controls in the UK Biobank cohort, including proportion of missing data. Results given as median (IQR) or n (%).
| Characteristic | Endometrial cancer cases (n=902) | Controls (n=221,129) |
|---|---|---|
| Age at recruitment, years | 61 (55-65) | 56 (49-62) |
| Duration of follow-up, years | 4.1 (2.6-5.7) | 7.2 (6.4-7.7) |
| BMI, kg/m2 | ||
| <25.0 | 204 (22.6) | 92048 (41.6) |
| 25.0-29.9 | 300 (33.3) | 79448 (35.9) |
| 30.0-34.9 | 190 (21.1) | 32373 (14.6) |
| 35.0-39.9 | 106 (11.8) | 11092 (5.0) |
| ≥40.0 | 94 (10.4) | 4983 (2.3) |
| Missing | 8 (0.9) | 1185 (0.5) |
| Ethnicity | ||
| White | 848 (94.0) | 207755 (94.0) |
| Black or Black British | 8 (0.9) | 3651 (1.7) |
| Mixed | 4 (0.4) | 1591 (0.7) |
| Indian | 14 (1.6) | 2514 (1.1) |
| Pakistani | 2 (0.2) | 634 (0.3) |
| Bangladeshi | 0 (0.0) | 62 (0.03) |
| Chinese | 4 (0.4) | 879 (0.4) |
| Other Asian | 3 (0.3) | 724 (0.3) |
| Other ethnic background | 14 (1.6) | 2192 (1.0) |
| Missing | 5 (0.6) | 1127 (0.5) |
| Family history of colorectal cancer | ||
| Yes | 117 (13.0) | 23037 (10.4) |
| No | 785 (87.0) | 198092 (89.6) |
| Smoking | ||
| Never | 586 (65.0) | 132288 (59.8) |
| Current/previous | 310 (34.4) | 87599 (39.6) |
| Missing | 6 (0.7) | 1242 (0.6) |
| Waist circumference, cm | 90 (81-101) | 82 (75-91) |
| Missing | 4 (0.4) | 904 (0.4) |
| Age at menarche, years | ||
| <12 | 233 (25.8) | 40685 (18.4) |
| ≥12 | 605 (67.1) | 160601 (72.6) |
| Missing | 64 (7.1) | 19843 (9.0) |
| Age at menopause, years | ||
| Pre-menopausal at study entry | 146 (16.2) | 72740 (32.9) |
| <55 | 568 (63.0) | 126502 (57.2) |
| ≥55 | 188 (20.8) | 21887 (9.9) |
| Age at last birth, years | 27 (18-31) | 29 (23-33) |
| Missing | 6 (0.7) | 1345 (0.6) |
| HRT use | ||
| Never/prior use | 790 (87.6) | 198695 (89.9) |
| Current use | 62 (6.9) | 12303 (5.6) |
| Missing | 50 (5.5) | 10131 (4.6) |
| Oral contraceptive pill use | ||
| <5 years or never use | 465 (51.6) | 79849 (36.1) |
| ≥5 years | 354 (39.3) | 121244 (54.8) |
| Missing | 83 (9.2) | 20036 (9.1) |
| Tamoxifen use | ||
| Current | 15 (1.7) | 1320 (0.6) |
| Never/prior use | 887 (98.3) | 219809 (99.4) |
| Type 2 diabetes | ||
| Yes | 73 (8.1) | 5587 (2.5) |
| No | 825 (91.5) | 214517 (97.0) |
| Missing | 4 (0.4) | 1025 (0.5) |
| Walking MET-h/week | 8.3 (4.4-23.1) | 11.6 (5.5-23.1) |
| Missing | 211 (23.4) | 48782 (22.1) |
| Moderate activity MET-h/week | 7.0 (1.3-18.7) | 8.0 (2.0-20.0) |
| Missing | 211 (23.4) | 48782 (22.1) |
| Vigorous MET-h/week | 2.0 (0.0-10.7) | 2.7 (0.0-12.0) |
| Missing | 211 (23.4) | 48782 (22.1) |